Evidence map›Paper›PMID 41484832›Full record

ArticleBMC gastroenterology2026

HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients.

Yandi Xie, Xiaojing Zhang, Xiaozhou Yang, Sujun Zheng, Shuyun Zhang, Xiaoying Zhang, Haiyan Kang, Xuefei Duan, Wenpin Cai, Peng Yin and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yandi XieInfectious Disease and Hepatology Center of Peking University People's Hospital，Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Peking University Hepatology Institute, Xizhimen South Street No. 11, Beijing, 100044, China.
Xiaojing ZhangHangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xiaozhou YangThe Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Sujun ZhengLiver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Shuyun ZhangThe Second Affiliated Hospital of Harbin Medical University, Heilongjiang, Haerbin, China.
Xiaoying ZhangTianjin Second People's Hospital, Tianjin, China.
Haiyan KangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Xuefei DuanDepartment of General Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wenpin CaiDepartment of Laboratory Medicine, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, Zhejiang, China.
Peng YinSansure Biotech Inc. LTD, 680 Lusong Rd, Yuelu District, Hunan, Changsha, 410205, China.
Xinghuan MaSansure Biotech Inc. LTD, 680 Lusong Rd, Yuelu District, Hunan, Changsha, 410205, China.
Juan LiuSansure Biotech Inc. LTD, 680 Lusong Rd, Yuelu District, Hunan, Changsha, 410205, China.
Fengmin LuDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian 22 District, Beijing, 100191, China. lu.fengmin@hsc.pku.edu.cn.
Lizhong DaiSansure Biotech Inc. LTD, 680 Lusong Rd, Yuelu District, Hunan, Changsha, 410205, China. lizhongd@sansure.com.cn.
Bo FengInfectious Disease and Hepatology Center of Peking University People's Hospital，Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Peking University Hepatology Institute, Xizhimen South Street No. 11, Beijing, 100044, China. fengbo@pkuph.edu.cn.

Funding

National Major Science and Technology Project of China No. 2017ZX10302201-004-001
6 · The paper itself

Abstract

backgroundThis multicenter study evaluated serum HBV RNA as a prognostic biomarker for nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB), focusing on correlations with HBV DNA/HBsAg and predictive value for virological response (VR) and HBeAg seroconversion.

methodsFrom 2020 to 2024, 427 treatment-naive HBeAg-positive CHB patients across nine Chinese hospitals were enrolled. Longitudinal HBV RNA-DNA-HBsAg correlations were analyzed during 24-month NA therapy. Predictive performance for VR at 12 months and HBeAg seroconversion at 24 months was assessed.

resultsNon-VR patients had higher baseline HBV DNA (median 7.42 vs. 5.38 log

conclusionsHBV RNA dynamics transition from DNA- to HBsAg-associated correlations during NA therapy. Early declines in HBV DNA/RNA at 6 months predict VR and HBeAg seroconversion, establishing this time as a a robust and clinically practical early prediction point. HBV RNA complements existing biomarkers for optimizing CHB management.

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B virusNucleosidesRNA, ViralAdultBiomarkersDNA, ViralFemaleHepatitis B e AntigensHepatitis B Surface AntigensHumansMaleMiddle AgedPredictive Value of TestsPrognosisAntiviral AgentsBiomarkersDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensNucleosidesRNA, ViralDNAHBeAgHepatitis B virusRNAVirological response

Identifiers

PMID41484832
PMCPMC12857138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.